Summary

Thrombin Market – Scope of Report
TMR’s report on the global thrombin market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global thrombin market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global thrombin market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the thrombin market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global thrombin market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global thrombin market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global thrombin market.

The report delves into the competitive landscape of the global thrombin market. Key players operating in the global thrombin market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global thrombin market profiled in this report.

Key Questions Answered in Global thrombin Market Report
• What is the sales/revenue generated by thrombin across all regions during the forecast period?
• What are the opportunities in the global thrombin market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Thrombin Market – Research Objectives and Research Approach
The comprehensive report on the global thrombin market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global thrombin market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global thrombin market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Thrombin Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Thrombin Market Analysis and Forecasts, 2023–2031
5. Key Insights
5.1. Current Trends in Thrombin
5.2. Technological advancements in Thrombin
5.3. COVID-19 Impact Analysis
6. Global Thrombin Market Analysis and Forecasts, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2023–2031
6.3.1. Bovine Thrombin
6.3.2. Human Thrombin
6.3.3. Recombinant Thrombin
6.4. Market Attractiveness Analysis, by Product
7. Global Thrombin Market Analysis and Forecasts, by Dosage Form
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Dosage Form, 2023–2031
7.3.1. Powder Form
7.3.2. Solution Form
7.3.3. Others
7.4. Market Attractiveness Analysis, by Dosage Form
8. Global Thrombin Market Analysis and Forecasts, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2023–2031
8.3.1. Hospitals
8.3.2. Diagnostic Centers & Clinics
8.3.3. Academic & Research Institutes
8.4. Market Attractiveness Analysis, by End-user
9. Global Thrombin Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Thrombin Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2023–2031
10.2.1. Bovine Thrombin
10.2.2. Human Thrombin
10.2.3. Recombinant Thrombin
10.3. Market Value Forecast, by Dosage Form, 2023–2031
10.3.1. Powder Form
10.3.2. Solution Form
10.3.3. Others
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Hospitals
10.4.2. Diagnostic Centers & Clinics
10.4.3. Academic & Research Institutes
10.5. Market Value Forecast, by Country, 2023–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Dosage Form
10.6.3. By End-user
10.6.4. By Country
11. Europe Thrombin Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2023–2031
11.2.1. Bovine Thrombin
11.2.2. Human Thrombin
11.2.3. Recombinant Thrombin
11.3. Market Value Forecast, by Dosage Form, 2023–2031
11.3.1. Powder Form
11.3.2. Solution Form
11.3.3. Others
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Hospitals
11.4.2. Diagnostic Centers & Clinics
11.4.3. Academic & Research Institutes
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Dosage Form
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Thrombin Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2023–2031
12.2.1. Bovine Thrombin
12.2.2. Human Thrombin
12.2.3. Recombinant Thrombin
12.3. Market Value Forecast, by Dosage Form, 2023–2031
12.3.1. Powder Form
12.3.2. Solution Form
12.3.3. Others
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Hospitals
12.4.2. Diagnostic Centers & Clinics
12.4.3. Academic & Research Institutes
12.5. 12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Dosage Form
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Thrombin Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2023–2031
13.2.1. Bovine Thrombin
13.2.2. Human Thrombin
13.2.3. Recombinant Thrombin
13.3. Market Value Forecast, by Dosage Form, 2023–2031
13.3.1. Powder Form
13.3.2. Solution Form
13.3.3. Others
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Hospitals
13.4.2. Diagnostic Centers & Clinics
13.4.3. Academic & Research Institutes
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Dosage Form
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Thrombin Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2023–2031
14.2.1. Bovine Thrombin
14.2.2. Human Thrombin
14.2.3. Recombinant Thrombin
14.3. Market Value Forecast, by Dosage Form, 2023–2031
14.3.1. Powder Form
14.3.2. Solution Form
14.3.3. Others
14.4. Market Value Forecast, by End-user, 2023–2031
14.4.1. Hospitals
14.4.2. Diagnostic Centers & Clinics
14.4.3. Academic & Research Institutes
14.5. Market Value Forecast, by Country/Sub-region, 2023–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Dosage Form
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Johnson & Johnson
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Pfizer, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Mallinckrodt Pharmaceuticals
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Shanghai RAAS Blood Products Co., Ltd.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Japan Blood Products Organization
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Mochida Pharmaceutical Co., Ltd.
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. BIOFAC A/S
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Biomed-Lublin S.A.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Hualan Biological Engineering, Inc.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis